

Vigfjós Sigurdsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/115930/publications.pdf>

Version: 2024-02-01

17
papers

215
citations

1040056

9
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

265
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. <i>Journal of Cutaneous Pathology</i> , 2000, 27, 436-440.	1.3	32
2	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. <i>Journal of Clinical Oncology</i> , 2021, 39, 1243-1252.	1.6	28
3	Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1494-1502.	1.5	25
4	Interleukin 4 and interferon- γ expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study. <i>Journal of Cutaneous Pathology</i> , 2000, 27, 429-435.	1.3	22
5	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2021, 157, 166.	4.1	21
6	Comparison of Survival Between Patients With Single vs Multiple Primary Cutaneous Melanomas. <i>JAMA Dermatology</i> , 2019, 155, 1049.	4.1	20
7	Subtyping Cutaneous Melanoma Matters. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa097.	2.9	17
8	Desmoplastic melanoma: The role of pure and mixed subtype in sentinel lymph node biopsy and survival. <i>Cancer Medicine</i> , 2020, 9, 671-677.	2.8	13
9	Health-related quality of life in patients with immune mediated inflammatory diseases: A cross-sectional, multidisciplinary study. <i>Clinical Immunology</i> , 2020, 214, 108392.	3.2	13
10	Posttraumatic unilateral perniosis: A case report. <i>JAAD Case Reports</i> , 2019, 5, 909-911.	0.8	4
11	Collodion babies: A 15-year retrospective multicenter study in The Netherlands—Evaluation of severity scores to predict the underlying disease. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1111-1113.	1.2	4
12	High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. <i>European Journal of Cancer</i> , 2021, 149, 105-113.	2.8	4
13	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. <i>European Journal of Cancer</i> , 2022, 167, 123-132.	2.8	4
14	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15mm in thickness). <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 298-305.	1.2	3
15	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. <i>European Journal of Cancer</i> , 2022, 167, 133-141.	2.8	3
16	Probability of sentinel lymph node positivity in melanoma. <i>European Journal of Cancer</i> , 2019, 116, 10-12.	2.8	2
17	ASO Author Reflections: Sentinel Lymph Node Biopsy Trend in Melanoma: The More the Merrier. <i>Annals of Surgical Oncology</i> , 2019, 26, 723-724.	1.5	0